U.S. judge rejects Novo Nordisk's bid to block Eli Lilly obesity drug ads

A U.S. federal judge denied Novo Nordisk's request to halt television advertisements by Eli Lilly for its obesity treatments.

Novo had argued the ads were misleading and sought an injunction, but the court found insufficient grounds to block them.

The ruling allows Lilly to continue its TV campaign, maintaining its competitive push in the rapidly growing obesity drug market.

The decision marks another legal setback for Novo as it continues to challenge competitors' marketing practices.